Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

JAMA Oncology - Tập 6 Số 5 - Trang 661 - 2020
Naiyer A. Rizvi1, Byoung Chul Cho2, Niels Reinmuth3, Ki Hyeong Lee4, Alexander Luft5, Myung‐Ju Ahn6, Michel M. van den Heuvel7, Manuel Cobo8, David Vicente9, Alexey Smolin10, Vladimir Moiseyenko11, Scott Antonia12, Sylvestre Le Moulec13, G. Robinet14, Ronald B. Natale15, Jeffrey Schneider16, Frances A. Shepherd17, Sarayut Lucien Geater18, Edward B. Garon19, Edward S. Kim20, Sarah B. Goldberg21, Kazuhiko Nakagawa22, Rajiv Raja23, Brandon W. Higgs23, Anne-Marie Boothman24, Luping Zhao23, Urban Scheuring24, Paul K. Stockman24, Vikram K. Chand23, Solange Peters25
1Division of Hematology/Oncology, Columbia University Medical Center, New York, New York
2Yonsei Cancer Center/Yonsei University College of Medicine, Seoul, South Korea
3Asklepios Lung Clinic, Munich-Gauting, Germany
4Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea
5Department of Oncology No. 1 (Thoracic Surgery), Leningrad Regional Clinical Hospital, St. Petersburg, Russia
6Department of Hematology and Oncology, Samsung Medical Center, Seoul, South Korea
7Nederlands Kanker Instituut–Antoni van Leeuwenhoekziekenhuis, Amsterdam, the Netherlands
8Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain
9Department of Medical Oncology, Hospital Universitario Virgen Macarena, Seville, Spain
10Department of Radiology, Burdenko Main Military Clinical Hospital, Moscow, Russia
11Oncological Clinical Research Center, St Petersburg, Russia
12H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
13Department of Medical Oncology, Institut Bergonié, Bordeaux, France
14Service de Pneumologie, Centre Hospitalier Régional Universitaire de Brest–Hôpital Morvan, Brest, France
15Cedars-Sinai Comprehensive Cancer Center, Los Angeles, California
16Department of Hematology and Oncology, NYU Winthrop Hospital, Mineola, New York
17Princess Margaret Cancer Centre and the Department of Medicine, University of Toronto, Toronto, Ontario, Canada
18Department of Internal Medicine, Prince of Songkla University, Songkhla, Thailand
19David Geffen School of Medicine, University of California/TRIO-US Network, Los Angeles
20Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
21Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut
22Faculty of Medicine, Department of Medical Oncology, Kindai University, Osaka, Japan
23AstraZeneca, Gaithersburg, Maryland
24AstraZeneca, Cambridge, United Kingdom
25Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland

Tóm tắt

Từ khóa


Tài liệu tham khảo

Mok, 2019, Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial., Lancet, 393, 1819, 10.1016/S0140-6736(18)32409-7

Gandhi, 2018, Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer., N Engl J Med, 378, 2078, 10.1056/NEJMoa1801005

Socinski, 2018, Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC., N Engl J Med, 378, 2288, 10.1056/NEJMoa1716948

West, 2019, Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial., Lancet Oncol, 20, 924, 10.1016/S1470-2045(19)30167-6

Papadimitrakopoulou, 2018, IMpower132: PFS and safety results with 1L atezolizumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC, J Thorac Oncol, 13, S332, 10.1016/j.jtho.2018.08.262

Paz-Ares, 2018, Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer., N Engl J Med, 379, 2040, 10.1056/NEJMoa1810865

Planchard, ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment for metastatic non-small cell lung cancer, Ann Oncol

Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma., N Engl J Med, 371, 2189, 10.1056/NEJMoa1406498

Rizvi, 2015, Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer., Science, 348, 124, 10.1126/science.aaa1348

Carbone, 2017, First-line nivolumab in stage IV or recurrent non-small-cell lung cancer., N Engl J Med, 376, 2415, 10.1056/NEJMoa1613493

Hellmann, 2018, Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden., N Engl J Med, 378, 2093, 10.1056/NEJMoa1801946

Ready, 2019, First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers., J Clin Oncol, 37, 992, 10.1200/JCO.18.01042

Higgs, 2018, High tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+ NSCLC patients (pts) treated with anti-PD-L1 and anti-CTLA-4., Ann Oncol, 29, i19, 10.1093/annonc/mdy269.063

Quinn, 2018, Development and analytical validation of a plasma-based tumor mutational burden (TMB) score from next-generation sequencing panels., Ann Oncol, 29, i41, 10.1093/annonc/mdy269.129

Kim, 2018, Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)., Ann Oncol, 29, i744, 10.1093/annonc/mdy424.067

Gandara, 2018, Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab., Nat Med, 24, 1441, 10.1038/s41591-018-0134-3

Qiu, 2019, Measuring tumor mutational burden (TMB) in plasma from mCRPC patients using two commercial NGS assays., Sci Rep, 9, 114, 10.1038/s41598-018-37128-y

Stewart, 2015, Identification and characterization of MEDI4736, an antagonistic anti–PD-L1 monoclonal antibody., Cancer Immunol Res, 3, 1052, 10.1158/2326-6066.CIR-14-0191

Antonia, 2017, Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer., N Engl J Med, 377, 1919, 10.1056/NEJMoa1709937

Antonia, 2018, Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC., N Engl J Med, 379, 2342, 10.1056/NEJMoa1809697

Garassino, 2018, Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study., Lancet Oncol, 19, 521, 10.1016/S1470-2045(18)30144-X

Kowalski, 2018, ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in=3L advanced NSCLC treatment., Ann Oncol, 29, i493, 10.1093/annonc/mdy292.001

Tarhini, 2008, Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers., Expert Opin Biol Ther, 8, 1583, 10.1517/14712598.8.10.1583

Chaft, 2018, Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC, Cancer Res, 78

Oken, 1982, Toxicity and response criteria of the Eastern Cooperative Oncology Group., Am J Clin Oncol, 5, 649, 10.1097/00000421-198212000-00014

Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)., Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Brahmer, 2014, Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC., J Clin Oncol, 32, 8021, 10.1200/jco.2014.32.15_suppl.8021

Antonia, 2019, Clinical activity, tolerability, and long-term follow-up of durvalumab in patients with advanced NSCLC., J Thorac Oncol, 14, 1794, 10.1016/j.jtho.2019.06.010

Ciuleanu, 2009, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study., Lancet, 374, 1432, 10.1016/S0140-6736(09)61497-5

Paz-Ares, 2013, PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer., J Clin Oncol, 31, 2895, 10.1200/JCO.2012.47.1102

Scagliotti, 2008, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer., J Clin Oncol, 26, 3543, 10.1200/JCO.2007.15.0375

Antonia, 2016, Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study., Lancet Oncol, 17, 299, 10.1016/S1470-2045(15)00544-6

Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer., N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643

Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer., N Engl J Med, 373, 123, 10.1056/NEJMoa1504627

Fehrenbacher, 2016, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial., Lancet, 387, 1837, 10.1016/S0140-6736(16)00587-0

Lan, 1983, Discrete sequential boundaries for clinical trials., Biometrika, 70, 659, 10.2307/2336502

Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer., N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774

Wu, 2017, A phase 3 study of first-line durvalumab vs platinum-based chemotherapy in patients with advanced NSCLC and high PD-L1 expression: PEARL, Ann Oncol, 28, v460

Samstein, 2019, Tumor mutational load predicts survival after immunotherapy across multiple cancer types., Nat Genet, 51, 202, 10.1038/s41588-018-0312-8

Hellmann, 2019, Nivolumab plus ipilimumab in advanced non-small-cell lung cancer., N Engl J Med, 381, 2020, 10.1056/NEJMoa1910231

Mao, 2017, Capture-based targeted ultradeep sequencing in paired tissue and plasma samples demonstrates differential subclonal ctDNA-releasing capability in advanced lung cancer., J Thorac Oncol, 12, 663, 10.1016/j.jtho.2016.11.2235

Murtaza, 2013, Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA., Nature, 497, 108, 10.1038/nature12065

Maio, 2017, Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial., Lancet Oncol, 18, 1261, 10.1016/S1470-2045(17)30446-1

AstraZeneca. Imfinzi and imfinzi plus tremelimumab delayed disease progression in phase III POSEIDON trial for 1st-line treatment of stage IV non–small cell lung cancer [press release]. https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-and-imfinzi-plus-tremelimumab-delayed-disease-progression-in-phase-iii-poseidon-trial-for-1st-line-treatment-of-stage-iv-non-small-cell-lung-cancer.html. October 28, 2019. Accessed November 20, 2019.

Thông tin
Thông tin xuất bản

JAMA Oncology

Tập 6 Số 5

661

Thông tin tác giả